| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Mogroside II-A2 targets metabolic and inflammatory pathways. Like other mogrosides, it exhibits antioxidant, antidiabetic, and anticancer properties. Its mechanism of action is believed to involve the modulation of AMPK and other metabolic regulators, similar to its aglycone, Mogrol. As a class, mogrosides are reported to possess these activities.
|
|---|---|
| ln Vitro |
In vitro, Mogroside II-A2 demonstrates biological activity consistent with the mogroside class. It exhibits antioxidant, antidiabetic, and anticancer properties. While it is not one of the most abundant mogrosides, it contributes to the overall bioactivity of monk fruit extracts. Its intense sweetness makes it a valuable compound for research into sweet taste and metabolism.
|
| ln Vivo |
In vivo, Mogroside II-A2 is believed to contribute to the overall health benefits of monk fruit. Its antidiabetic and antioxidant effects are thought to be relevant for metabolic health. As a component of monk fruit extracts, it may play a role in the observed benefits of these extracts in animal models of diabetes and obesity. Specific standalone in vivo data are limited.
|
| Enzyme Assay |
The in vitro antioxidant assay for Mogroside II-A2 involves measuring its ability to scavenge free radicals, such as DPPH or ABTS. The compound is incubated with the radical, and the decrease in absorbance is measured. For antidiabetic activity, its effect on glucose uptake in skeletal muscle cells or its ability to inhibit α-glucosidase can be measured.
|
| Cell Assay |
In vitro cell culture studies for Mogroside II-A2 utilize various cell lines to study its bioactivity. Its anticancer activity is assessed in cancer cell lines using MTT assays. Its anti-inflammatory effects can be studied in macrophage cell lines by measuring cytokine production. Its effect on glucose metabolism can be studied in skeletal muscle or liver cells.
|
| Animal Protocol |
In vivo animal experiments for Mogroside II-A2 are not extensively documented. However, its effects on glucose homeostasis could be studied in rodent models of type 2 diabetes. The compound would be administered orally, and its effect on blood glucose levels would be measured in an oral glucose tolerance test (OGTT). Its anti-inflammatory effects could be studied in models of acute inflammation.
|
| ADME/Pharmacokinetics |
Mogroside II-A2 has a molecular formula of C42H72O14 and a molecular weight of 801.01 g/mol. It is a solid compound that is soluble in water and organic solvents like DMSO. As a glycoside, it is more polar than its aglycone. It is typically stored as a powder at -20°C for long-term stability. Its stability is maintained under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for Mogroside II-A2 are limited, as it is a research compound. As a natural component of monk fruit, it is generally recognized as safe for human consumption at dietary levels. However, as a research compound, it is not intended for therapeutic use, and comprehensive toxicity studies are not available. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
Monk fruit glycoside II-A2 is a steroidal saponin, a 3-hydroxysteroid and disaccharide derivative.
Mogroside II-A2 is a research compound with no clinical approval. It is a valuable tool for studying the pharmacology of mogrosides and their potential applications in metabolic diseases. Its intense sweetness and bioactivity make it a compound of interest for research into sweet taste receptors, metabolism, and the development of functional foods. |
| Molecular Formula |
C42H72O14
|
|---|---|
| Molecular Weight |
801.0127
|
| Exact Mass |
800.492
|
| CAS # |
88901-45-5
|
| PubChem CID |
102594495
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
914.2±65.0 °C at 760 mmHg
|
| Flash Point |
506.7±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.602
|
| LogP |
3.46
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
56
|
| Complexity |
1410
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
C[C@H](CC[C@H](C(C)(C)O)O)C1CC[C@@]2([C@@]1(C[C@H]([C@@]3(C2CC=C4C3CC[C@@H](C4(C)C)OC5[C@@H]([C@H]([C@@H]([C@H](O5)CO[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O)O)C)O)C)C
|
| InChi Key |
SLAWMGMTBGDBFT-UMIXZHIDSA-N
|
| InChi Code |
InChI=1S/C42H72O14/c1-20(9-13-27(44)39(4,5)52)21-15-16-40(6)26-12-10-22-23(42(26,8)28(45)17-41(21,40)7)11-14-29(38(22,2)3)56-37-35(51)33(49)31(47)25(55-37)19-53-36-34(50)32(48)30(46)24(18-43)54-36/h10,20-21,23-37,43-52H,9,11-19H2,1-8H3/t20-,21?,23?,24-,25-,26?,27-,28-,29+,30-,31-,32+,33+,34-,35-,36-,37?,40+,41-,42+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R)-6-[[(3S,9R,11R,13R,14S)-17-[(2R,5R)-5,6-dihydroxy-6-methylheptan-2-yl]-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~124.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2484 mL | 6.2421 mL | 12.4842 mL | |
| 5 mM | 0.2497 mL | 1.2484 mL | 2.4968 mL | |
| 10 mM | 0.1248 mL | 0.6242 mL | 1.2484 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
